The Association between Human Papillomavirus Infection and Smoking, Age, Gender in Lung Cancer Patients: A Meta-Analysis

Zhang, Rui; Chen, Ling; Cui, Ya-Deng; Ge, Li

doi:10.18502/ijph.v48i1.777

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, miR-96 showed significantly higher diagnostic potential (AUC = 0.9735) than miR-1246 (AUC = 0.6761). Wu et al (100) focused on human papillomavirus (HPV) infection, which seems to be a dangerous risk factor in cancer patients (136)(137)(138). They found that miR-183, miR-210, and miR-182 were significantly higher, and miR-144 was markedly lower in HPV-DNA-positive NSCLC than in HPV-DNA-negative NSCLC patients.…”

Section: Circulating Mirnas As Diagnostic Biomarkers For Nsclcmentioning

confidence: 99%

Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients

et al. 2023

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) comprises 85% of all lung cancers and is a malignant condition resistant to advanced-stage treatment. Despite the advancement in detection and treatment techniques, the disease is taking a deadly toll worldwide, being the leading cause of cancer death every year. Current diagnostic methods do not ensure the detection of the disease at an early stage, nor can they predict the risk of its development. There is an urgent need to identify biomarkers that can help predict an individual’s risk of developing NSCLC, distinguish NSCLC subtype, allow monitor disease and treatment progression which can improve patient survival. Micro RNAs (miRNAs) represent the class of small and non-coding RNAs involved in gene expression regulation, influencing many biological processes such as proliferation, differentiation, and carcinogenesis. Research reports significant differences in miRNA profiles between healthy and neoplastic tissues in NSCLC. Its abundant presence in biofluids, such as serum, blood, urine, and saliva, makes them easily detectable and does not require invasive collection techniques. Many studies support miRNAs’ importance in detecting, predicting, and prognosis of NSCLC, indicating their utility as a promising biomarker. In this work, we reviewed up-to-date research focusing on biofluid miRNAs’ role as a diagnostic tool in NSCLC cases. We also discussed the limitations of applying miRNAs as biomarkers and highlighted future areas of interest.

show abstract

Section: Circulating Mirnas As Diagnostic Biomarkers For Nsclcmentioning

confidence: 99%

Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Additionally, a Chinese a study developed to identify the association between HPV positive rate and smoking in lung cancer (LC) patients observed that HPV infections are associated with smoking in LC patients and the association may relate to different regions [23]. Lung cancer study of Brazilian patients, the presence of HPV was detected by PCR followed by genotyping, found HPV in 33 of the 63 samples, and HPV types 16 and 18 were detected with frequencies of 81% (27/33) and 19% (6/33), respectively.…”

Section: Introductionmentioning

confidence: 99%

Human papillomavirus is not associated to non-small cell lung cancer: data from a prospective cross-sectional study

Silva

Mariano

Pastrez

et al. 2019

Infect Agents Cancer

View full text Add to dashboard Cite

Background: The pathogenesis of lung cancer is triggered by a combination of genetic and environmental factors, being the tobacco smoke the most important risk factor. Nevertheless, the incidence of lung cancer in non-smokers is gradually increasing, which demands the search for different other etiological factors such as occupational exposure, previous lung disease, diet among others. In the early 80's a theory linked specific types of human papillomavirus (HPV) to lung cancer due to morphological similarities of a subset of bronchial squamous cell carcinomas with other HPV-induced cancers. Since then, several studies revealed variable rates of HPV DNA detection. The current study aimed to provide accurate information on the prevalence of HPV DNA in lung cancer.Methods: Biopsies were collected from 77 newly diagnosed non-small cell lung cancer (NSCLC) patients treated at the Thoracic Oncology Department at Barretos Cancer Hospital. The samples were formalin fixed and paraffin embedded (FFPE), histologic analysis was performed by an experienced pathologist. DNA was extracted from FFPE material using a commercial extraction kit and HPV DNA detection was evaluated by multiplex PCR and HPV16 specific real-time PCR. Results: HPV was not identified in any of the samples analysed (69). Conclusions:Our data demonstrated a lack of HPV DNA in a series of NSCL cancers.

show abstract

“…Cellular Microbiology successful even with the above features when applied together [44]. In the literature, HPV prevalence and activity still are controversial [3,45]. The difference between HPV detection in lung samples may vary due to increased sensitivity of qPCR compared to the conventional PCR screening, DNA extraction method, and geographic location [43,[46][47][48][49].…”

mentioning

confidence: 99%

Correlation between HPV PCNA, p16, and p21 Expression in Lung Cancer Patients

Marcos

Oliveira

Amaral

et al. 2022

Cellular Microbiology

View full text Add to dashboard Cite

Purpose. Evaluate if human papillomavirus (HPV) infection in lung cancer patients might be helping cancer development by altering p16, p21, and PCNA, key human genes involved in cell proliferation and tumor development. Methods. 63 fresh-frozen (FF) and formalin-fixed paraffin-embedded (FFPE) samples from lung tumor patients were used to detect HPV by PCR, followed by genotype through sequencing. The host gene expressions of p21, p16, and PCNA were quantified by qPCR in both FF and FFPE samples, and the expression of viral oncogenes E5, E6, and E7 was also measured by qPCR in 19 FF samples. Results. 74.6% of samples were positive for HPV, 33/44 FFPE samples and 14/19 FF samples. HPV-16 and HPV-18 were detected in 31/33 and 7/33 FFPE, respectively, and HPV-16 was the only type in FF samples. E5, E6, and E7 were expressed in 10/19, 2/19, and 4/19 FF samples, respectively. The p16 RNAm expression was higher in FF HPV+ samples and FFPE+FF HPV+ samples, while p21 showed higher expression in all HPV- samples. In turn, the PCNA expression was higher in HPV+ FF samples; however, in FFPE and FFPE+FF samples, PCNA was higher in HPV- samples. In FF samples, PCNA, p16, and p21 showed a significant positive correlation as well as E5 and E7, and E5 was inversely correlated to p21. In FFPE, also, a positive correlation was observed between PCNA HPV+ and p21 HPV+ and PCNA HPV+ and p16 HPV. In FF+FFPE analysis, a direct correlation was found between PCNA HPV+ and p21 HPV+, p21 HPV+ and p16 HPV+, and PCNA HPV- and p16 HPV-, and an inverse correlation between PCNA HPV+ and p16 HPV+. Also, the p16 protein was positive in 10 HPV+ samples and 1 HPV-. Conclusions. Our data show that lung cancer patients from Northeast Brazil have a high prevalence of HPV, and the virus also expresses its oncogenes and correlates with key human genes involved in tumor development. This data could instigate the development of studies focused on preventive strategies, such as vaccination, used as a prognostic indicator and/or individualized therapy.

show abstract

The Association between Human Papillomavirus Infection and Smoking, Age, Gender in Lung Cancer Patients: A Meta-Analysis

Cited by 3 publications

References 23 publications

Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients

Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients

Human papillomavirus is not associated to non-small cell lung cancer: data from a prospective cross-sectional study

Correlation between HPV PCNA, p16, and p21 Expression in Lung Cancer Patients

Contact Info

Product

Resources

About